Quick answers
- What is Ofloxacin used for?
- The FDA-approved label (Ocuflox, Allergan, Inc., June 13, 2024) says: “OCUFLOX ® ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Enterobacter cloacae Staphylococcus epidermidis Haemophilus influenzae Streptococcus pneumoniae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Ofloxacin have a boxed warning?
- The label we quote has no boxed warning, but 2 of 71 FDA labels for this medicine do. Check the label of your own product.
- Is there a shortage of Ofloxacin?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Ofloxacin been recalled?
- FDA enforcement reports list 2 recalls of products of this medicine; the newest started April 13, 2022 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Ofloxacin?
- 29 companies list prescription products of Ofloxacin in the FDA NDC Directory, including A-S Medication Solutions, NuCare Pharmaceuticals, Inc. and Proficient Rx LP.
What Ofloxacin is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
OCUFLOX ® ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Enterobacter cloacae Staphylococcus epidermidis Haemophilus influenzae Streptococcus pneumoniae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS …
— FDA label: Ocuflox, Allergan, Inc., effective June 13, 2024. Read the full label on DailyMed →
The FDA has 71 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
2 of 71 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Solution · Solution/ drops · Tablet, film coated |
|---|---|
| Route | Ophthalmic · Auricular (otic) · Oral |
| Prescription products | 88 in the FDA NDC Directory |
| Brand names | Ocuflox |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| ofloxacin 3 mg/mL solution | Generic | $0.9940–$1.23 per mL 20 packages, lowest to highest |
| ofloxacin 3 mg/mL solution/ drops | Generic | $0.9940–$1.23 per mL 19 packages, lowest to highest |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- A-S Medication Solutions10 products
- NuCare Pharmaceuticals, Inc.9 products
- Proficient Rx LP8 products
- Remedyrepack Inc.6 products
- Lifestar Pharma LLC4 products
- Caplin Steriles Limited4 products
- Preferred Pharmaceuticals Inc.4 products
- Cadila Pharmaceuticals Limited3 products
- Somerset Therapeutics, LLC3 products
- Modavar Pharmaceuticals LLC3 products
- Redpharm Drug3 products
- Direct_Rx3 products
- Bryant Ranch Prepack3 products
- NorthStar RxLLC2 products
- Asclemed USA, Inc.2 products
- Bausch & Lomb Incorporated2 products
- Rising Pharma Holdings, Inc.2 products
- Apotex Corp.2 products
- Leading Pharma, LLC2 products
- St. Mary's Medical Park Pharmacy2 products
- Amneal Pharmaceuticals NY LLC2 products
- Sportpharm LLC2 products
- Allergan, Inc.1 product
- SOLA Pharmaceuticals, LLC1 product
- Altaire Pharmaceuticals Inc.1 product
- NuCare Pharmceuticals, Inc.1 product
- Armas Pharmaceuticals Inc.1 product
- Micro Labs Limited1 product
- Major Pharmaceuticals1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA019921 OCUFLOX | Allergan | July 30, 1993 | 15, latest November 16, 2016 2016: Labeling · 2002: Manufacturing (CMC) · 2001: Manufacturing (CMC) |
Generic approvals (17)
- ANDA076513Apotex Inc · May 14, 2004
- ANDA076622Bausch and Lomb · May 14, 2004
- ANDA076527Apotex Inc · September 28, 2007
- ANDA076128Bausch and Lomb Inc · March 17, 2008
- ANDA076407Sentiss · April 15, 2008
- ANDA078559Fdc Ltd · February 25, 2009
- ANDA202692Altaire Pharms Inc · April 29, 2013
- ANDA091656Cadila Pharms Ltd · September 18, 2014
- ANDA211525Amneal · August 30, 2019
- ANDA215038Fdc Ltd · January 19, 2022
- ANDA216130Mankind Pharma · July 14, 2022
- ANDA215886Mankind Pharma · November 23, 2022
- ANDA217903Caplin · January 5, 2024
- ANDA217904Caplin · April 12, 2024
- ANDA213597Somerset · August 1, 2024
- ANDA216328Somerset Theraps LLC · October 15, 2024
- ANDA218557Micro Labs · April 8, 2026
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
April 13, 2022 · Class II · Terminated · D-1114-2022
cGMP deviations: Temperature abuse
Ofloxacin Otic Solution 0.3%, 5 mL bottle, Rx only, MFG: Amneal/Akyma Pharmaceuticals, NDC 69238-1615-3 — Mckesson Medical-Surgical Inc. Corporate Office
-
July 2, 2019 · Class II · Completed · D-0436-2020
Lack of Assurance of Sterility
Ofloxacin Ophthalmic Solution, USP, 0.3%, 5 mL, Rx only, Altaire Pharmaceuticals, Inc., NDC 59390-140-05 — Altaire Pharmaceuticals, Inc.
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Ocuflox, Allergan, Inc., effective June 13, 2024; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →